London +4420 814 42225
Moscow +7495 543 9194
Kiev +38044 599 2950
info@mrcplast.com

Our Clients

Order Informer

 
Home > News >
 

ATS Automation gets USD20 million order for COVID-19 vaccine syringe manufacturing line

September 21/2020

MOSCOW (MRC) -- ATS Automation Tooling Systems has received a USD20 million order from a medical device manufacturer to design, build, and deliver several automated safety syringe manufacturing systems to meet potential demand related to COVID-19 vaccine production, said Canplastics.

The Cambridge, Ont.-based manufacturer, which specializes in custom and repeat automation in a range of industries including life sciences, is developing the systems for a program related to the U.S. governments Operation Warp Speed initiative, which seeks to increase the ability to produce safety needles and syringes in the U.S.

The automated systems will feature ATS new Symphoni digital manufacturing technology, which adds to the productivity of automated assembly processes by eliminating non-value-added production time.

In a statement, ATS said the high degree of standardization, modular building blocks and plug-and-play nature means Symphoni systems are multi-purpose production assets, and have the flexibility to adapt to new products and new processes.

Symphoni systems are 100 per cent programmable, so all movements are precisely mapped out and synchronized through a technique known as electronic gearing, resulting in a symphony of motion." It meets the manufacturing demands of high-volume consumables such as syringes because it assembles them at very high rates in a compact footprint while assuring compliance to the medical device industrys rigid quality standards.

"Our teams remain focused on helping manufacturers address the critical need for medical equipment brought on by the COVID-19 pandemic," said ATS CEO Andrew Hider in the statement.

The program will be completed over the next 10 months.

As MRC informed earlier, European Parliament says that the EU should become more self-sufficient in medicines and medical equipment so that affordable treatments are available at any time. It calls for priority to be given to boosting domestic production of essential and strategic medicines because currently 40% of medicines marketed in the EU originate in non-EU countries and 60-80% of its active pharmaceutical ingredient (API) supplies are produced in China and India.

According to MRC's ScanPlast report, Russia's overall PE production totalled 1,712,400 tonnes in the first seven months of 2020, up by 58% year on year. Linear low density polyethylene (LLDPE) accounted for the greatest increase in the output. At the same time, overall PP production in Russia increased in January-July 2020 by 24% year on year to 1,063,700 tonne. ZapSibNeftekhim accounted for the main increase in the output.


mrcplast.com
Author:Anna Larionova
Tags:PP, PE, injection moulding, medical supplies, Medicine, medical equipment, COVID-19.
Category:General News
|
| More

Leave a comment

MRC help

 


 All News   News subscribe